Investor Presentaiton
Financial Forecasts for FY2023
Segment Information (Core Basis)
Billions of yen
Japan segment: Profit will increase due
to the effects of reduced SG&A expenses,
while revenue will decrease
North America segment: Gross profit
will decrease significantly due to the
decrease in revenue. Profit is expected to
decline significantly, while cost reduction
through streamlining is expected
China segment: Profit will decrease
because revenue decrease largely
Other Regions segment: Decreased
revenue and profit due to one-time
payments based on out-licensing
agreements in FY2021
Other Business: Revenue will decrease
due to the transfer of two subsidiaries
and profit will decrease due to a
decrease in transfer gains
Pharmaceuticals Business
North
Other
Japan
China
Subtotal
Other
Business
Total
America
Regions
Revenue (Sales to customers)
105.0
208.8
33.0
13.7
360.5
1.5
362.0
Cost of sales
48.1
68.8
7.4
6.8
131.1
0.9
132.0
Gross profit
56.9
140.0
25.6
6.9
229.4
0.6
230.0
SG&A expenses
46.1
160.3
10.6
1.8
218.8
1.2
220.0
Core segment profit
10.8
(20.3)
15.0
5.1
10.6
(0.6)
10.0
R&D expenses
82.0
2.0
84.0
Core operating profit
(65.4)
3.4
(62.0)
Revenue (Sales to customers)
126.1
328.5
39.4
16.8
510.7
44.8
555.5
Cost of sales
65.3
62.4
8.4
5.1
141.3
35.4
176.7
Gross profit
60.9
266.0
31.0
11.6
369.5
9.3
378.8
SG&A expenses
51.8
233.8
11.4
1.6
298.7
7.0
305.6
Core segment profit
9.1
32.2
19.5
10.0
70.8
2.4
73.2
R&D expenses
103.2
2.8
106.1
Core operating profit
(8.0)
24.3
16.4
Revenue (Sales to customers)
(21.1) (119.7) (6.4)
(3.1)
(150.2)
(43.3) (193.5)
SG&A expenses
(5.7)
(73.6)
(0.8)
0.2
(79.9)
(5.8) (85.6)
Core segment profit
1.7
(52.5)
(4.5)
(4.9)
(60.2) (3.0)
(63.2)
R&D expenses
Core operating profit
Sumitomo Pharma
(21.2) (0.8)
(22.1)
(57.4)
(21.0)
(78.4)
FY2023 Forecasts
FY2022 Results
Change
© Sumitomo Pharma Co., Ltd. All Rights Reserved. 12View entire presentation